Close

Anti-NS3 T cell receptor (D13), pCDTCR1 (TCR-YC0749)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-NS3 T cell receptor (TCR) is constructed for the engineering of T cell to target DENV2 NS3 (133–142) (GTSGSPIVDR) restricted by HLA-A*11:01. The T cells are genetically modified through transduction with a lentiviral vector expressing NS3-specific T cell receptor.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • NS3
  • Target Species
  • DENV2
  • Epitope
  • GTSGSPIVDR
  • Format
  • Non-Modified TCR
  • Allele
  • HLA-A*11:01
  • Targeting Diseases
  • DENV infection
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • D13
  • Host Species
  • Human

Target

  • Introduction
  • DENV belongs to the family Flaviviridae and contains a positive sense capped single strand RNA genome of ∼11 kb in size encoding ten proteins as a single open reading frame that is flanked by 5′ and 3′ untranslated region (UTR) regions that regulate translation and replication. Following direct translation, the polyprotein is co- and post-translationally processed by host and viral proteases to generate three structural and seven non-structural (NS) proteins NH3+ C-prM-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5 COO−. NS3 and NS5 contain all the enzymatic activities required for viral life cycle and have been extensively studied.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human anti-NS3 T cell receptor (D13), pCDTCR1 (TCR-YC0749). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.